Exelixis (EXEL) Short-term Investments (2010 - 2026)
Exelixis' (EXEL) quarterly Short-term Investments came in at $551.1 million in Q2 2026, down 34.98% year-on-year from $847.6 million in Q2 2025, and down 4.43% quarter-over-quarter from $576.6 million in Q1 2026.
Exelixis (EXEL) Short-term Investments (2010 - 2026) Analysis & Trends
Exelixis' Short-term Investments history runs 17 years deep, the most recent figure standing at $551.1 million for Q2 2026.
- On a quarterly basis, Short-term Investments fell 34.98% year-over-year to $551.1 million in Q2 2026; TTM through Apr 2026 was $551.1 million, a 34.98% decrease from a year earlier, with the FY2026 full-year figure at $576.6 million, down 35.5% from the prior year.
- Short-term Investments declined to $551.1 million in Q2 2026 per EXEL's latest filing, from $576.6 million in the prior quarter.
- Across five years, Short-term Investments topped out at $930.8 million in Q3 2024 and bottomed at $551.1 million in Q2 2026.
- The 5-year median for Short-term Investments is $802.3 million (2023), against an average of $764.3 million.
- Across the five-year window, Short-term Investments jumped 31.74% in 2024 and slumped 35.5% in 2026, its largest moves.
- Year by year, Short-term Investments stood at $807.3 million in 2022, then slipped by 9.29% to $732.3 million in 2023, then increased by 27.11% to $930.8 million in 2024, then tumbled by 34.23% to $612.2 million in 2025, then decreased by 9.99% to $551.1 million in 2026.
- Per Business Quant, the three latest EXEL Short-term Investments figures stand at $551.1 million (Q2 2026), $576.6 million (Q1 2026), and $612.2 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 551.06 Mn |
| Jan 2, 2026 | 576.60 Mn |
| Oct 3, 2025 | 612.24 Mn |
| Jul 4, 2025 | 626.67 Mn |
| Apr 4, 2025 | 847.56 Mn |
| Jan 3, 2025 | 893.90 Mn |
| Sep 27, 2024 | 930.82 Mn |
| Jun 28, 2024 | 803.54 Mn |
| Mar 29, 2024 | 703.70 Mn |
| Dec 29, 2023 | 732.31 Mn |
| Sep 29, 2023 | 706.53 Mn |
| Jun 30, 2023 | 802.34 Mn |
| Mar 31, 2023 | 772.54 Mn |
| Dec 30, 2022 | 807.27 Mn |
| Sep 30, 2022 | 871.71 Mn |
| Jul 1, 2022 | 907.94 Mn |
| Apr 1, 2022 | 847.06 Mn |
| Dec 31, 2021 | 819.91 Mn |
| Oct 1, 2021 | 835.41 Mn |
| Jul 2, 2021 | 854.17 Mn |